<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00055198</url>
  </required_header>
  <id_info>
    <org_study_id>3009-012</org_study_id>
    <secondary_id>DAP-EAP-02-01</secondary_id>
    <nct_id>NCT00055198</nct_id>
  </id_info>
  <brief_title>Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria</brief_title>
  <official_title>A Compassionate Use Protocol for Intravenous Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria That Cannot be Adequately Treated With Currently Available Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cubist Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cubist Pharmaceuticals LLC</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide daptomycin, an antibiotic, to patients who are&#xD;
      failing conventional therapy, or who cannot take approved antibiotics for one reason or&#xD;
      another.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to low enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">December 19, 2002</start_date>
  <completion_date type="Actual">January 26, 2004</completion_date>
  <primary_completion_date type="Actual">January 26, 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>75</enrollment>
  <condition>Gram-Positive Bacterial Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daptomycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Infection caused by Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus&#xD;
             faecalis, or Enterococcus faecium that requires inpatient hospitalization and&#xD;
             treatment with injectable antibiotics**&#xD;
&#xD;
          -  Site of infection: complicated skin and skin structure infection; urinary tract&#xD;
             infection; intra-abdominal infection; infective endocarditis; or bloodstream infection&#xD;
             (including catheter-related).&#xD;
&#xD;
          -  Pathogen resistant to, or patient intolerant of: beta-lactams, vancomycin,&#xD;
             quinupristin/dalfopristin, or linezolid.&#xD;
&#xD;
          -  Unable to receive any other standard commercially available antibacterial therapy for&#xD;
             the infection.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Creatinine clearance less than 40 mL/min**&#xD;
&#xD;
          -  Hemodialysis or peritoneal dialysis&#xD;
&#xD;
          -  Admitted to the hospital for drug overdose or other conditions associated with&#xD;
             rhabdomyolysis, or is expected to require repeated intramuscular injections&#xD;
&#xD;
          -  Creatine phosphokinase (CPK) level greater than 2.5 times above the upper limit of&#xD;
             normal (ULN) at screening; if the elevation in CPK can be attributed to an obvious&#xD;
             cause (eg, surgery)**&#xD;
&#xD;
          -  Central nervous system infection&#xD;
&#xD;
          -  Pulmonary infection.&#xD;
&#xD;
        (**) An exemption may be granted for patients not satisfying these criteria following a&#xD;
        conversation with the Medical Monitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>February 20, 2003</study_first_submitted>
  <study_first_submitted_qc>February 20, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2003</study_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gram positive bacterial infections</keyword>
  <keyword>expanded access program</keyword>
  <keyword>resistant infections</keyword>
  <keyword>bacteremia</keyword>
  <keyword>Bacterial and fungal infections</keyword>
  <keyword>bacterial infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Gram-Positive Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daptomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

